A synthesis of the platelet aggregation inhibitor xemilofiban from L-aspartic acid. Confirmation of the absolute configuration

Tetrahedron Letters

Volumn 39, Issue 21, 1998, Pages 3449-3450

  Boys, Mark L ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[4 [[4 (AMINOIMINOMETHYL)PHENYL]AMINO] 1,4 DIOXOBUTYL]AMINO] 4 PENTYNOIC ACID; ANTITHROMBOCYTIC AGENT; ASPARTIC ACID; FIBRINOGEN; XEMILOFIBAN;

ARTICLE; DRUG CONFORMATION; DRUG SYNTHESIS; THROMBOCYTE AGGREGATION INHIBITION;

EID: 0032554980     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4039(98)00602-9     Document Type: Article

References (9)

1. Zablocki, J. A.; Rico, J. G.; Garland, R. B.; Rogers, T. E.; Williams, K.; Schretzman, L. A.; Rao, S. A.; Bovy, P. R.; Tjoeng, F. S.; Lindmark, R. J; Toth, M.; Zupec, M.; McMackins, D. E.; Adams, S. P.; Miyano, M; Markos, C. S.; Milton, M. N.; Paulson, S.; Herin, M.; Jacquin, P.; Nicholson, N.; Panzer-Knodle, S. G.; Haas, N. F.; Page, J. D.; Szalony, J. A.; Taite, B. B.; Salyers, A. K.; King, L. W.; Campion, J. G.; Feigen, L. P. J. Med. Chem. 1995;38:2378-2394.
2. Babiak, K.; Babu, S.; Behling, J. R.; Boys, M. L.; Cain-Janicki, K. J.; Doubleday, W. W.; Farid, P.; Hagen, T. J.; Hallinan, E.A.; Hansen, D. W., Jr.; Korte, D. E.; McLaughlin, K. T.; Medich, J. R.; Nugent, S. T.; Orlovski, V.; Park, J. M.; Peterson, K. B.; Pilipauskas, D. R.; Pitzele, B. S.; Tsymbalov, S.; Stahl, G. L. US Patent 5536869, July 16, 1996.
3. Cossy, J.; Schmitt, A.; Cinquin, C.; Buisson, D.; Belotti, D. Biorg. Med. Chem. Lett. 1997;7:1699-1700.
4. Ohkubo, M.; Takahashi, F.; Yamanaka, T.; Sakai, H.; Kato, M. International Patent WO 9508536.
5. Salzmann, T. N.; Ratcliffe, R. W.; Christensen, B. G.; Bouffard, F. A. J. Am. Chem. Soc. 1980;102:6163-6165.
6. Labia, R.; Morin, C. Chem. Lett. 1984:1007-1008.
7. Corey, E. J.; Fuchs, P. L. Tetrahedron Lett. 1972;13:3769-3772.
8. The author would like to thank Mr R. Salzmann for his expert technical assistance.
9. 13C NMR, IR, optical rotation and microanalysis.